AN2 Therapeutics (ANTX) Net Income towards Common Stockholders (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Net Income towards Common Stockholders of -$10.0 million for Q1 2026, up 5.83% year-over-year from -$9.5 million in Q1 2025, and down 15.13% quarter-over-quarter from -$8.7 million in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$10.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 5.83% year-over-year to -$10.0 million; the TTM figure through Mar 2026 stood at -$34.6 million (up 23.81% YoY), while the FY2025 annual figure was -$35.2 million, up 31.46% from the prior year.
- Net Income towards Common Stockholders declined to -$10.0 million in Q1 2026 per ANTX's latest filing, from -$8.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$6.5 million in Q2 2025 and bottomed at -$16.9 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$12.0 million across 5 years, with a median of -$11.3 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 237.31% — and 2024, when it soared 55.49%.
- AN2 Therapeutics' Net Income towards Common Stockholders stood at -$11.8 million in 2022, then plunged by 42.7% to -$16.9 million in 2023, then jumped by 55.49% to -$7.5 million in 2024, then retreated by 15.79% to -$8.7 million in 2025, then declined by 15.13% to -$10.0 million in 2026.
- Business Quant data shows ANTX's Net Income towards Common Stockholders at -$10.0 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -8.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.19 Mn |
| Mar 31, 2026 | -10.03 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Sep 30, 2025 | -9.35 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Mar 31, 2025 | -10.65 Mn |
| Dec 31, 2024 | -7.52 Mn |
| Sep 30, 2024 | -12.75 Mn |
| Jun 30, 2024 | -14.44 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -16.90 Mn |
| Sep 30, 2023 | -16.71 Mn |
| Jun 30, 2023 | -15.80 Mn |
| Mar 31, 2023 | -15.32 Mn |
| Dec 31, 2022 | -11.84 Mn |
| Sep 30, 2022 | -11.34 Mn |
| Jun 30, 2022 | -10.12 Mn |
| Mar 31, 2022 | -9.48 Mn |
| Dec 31, 2021 | -9.47 Mn |
| Sep 30, 2021 | -8.87 Mn |